GlassScriptPhysician profile
Felicia Pharagood
NPI 1649357831
$143,797.17
in general payments reported to CMS, 2019-2025
17 companies · $13K in 2025
The $13K reported for 2025 was more than what 99% of Emergency Medicine providers received nationally (typical 2025 total: $57.10).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,194 · 2020: $25K · 2021: $32K · 2022: $33K · 2023: $15K · 2024: $17K · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $36K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,407 · Food and Beverage: $67.39.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $35,651.67 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,407.04 |
| Food and Beverage | $67.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eli Lilly and Company | $69,997.82 | 2019-2024 | |
| Biomarin Pharmaceutical INC. | $16,902.43 | 2021-2024 | Voxzogo 1.2mg |
| Novo Nordisk INC | $12,196.87 | 2019-2020 | |
| Vertex Pharmaceuticals Incorporated | $11,713.33 | 2019-2023 | |
| Pacira Pharmaceuticals Incorporated | $9,455.00 | 2025 | Exparel, Iovera |
| Amgen INC. | $7,505.00 | 2021-2024 | Lumakras, Tezspire |
| Actelion Pharmaceuticals, LTD | $3,520.00 | 2022 | |
| Viiv Healthcare Company | $2,600.00 | 2025 | |
| Incyte Corporation | $2,475.00 | 2022 | |
| H. Lundbeck A S | $2,300.00 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $1,625.00 | 2022 | |
| Daiichi Sankyo INC. | $1,011.00 | 2022 | |
| Zoll Medical Corporation | $559.17 | 2024 | Defibrillator |
| Becton, Dickinson and Company | $558.15 | 2020 | |
| Johnson & Johnson Health Care Systems INC. | $500.00 | 2025 | Spravato |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus Corporation of The Americas | $494.10 | 2022 | |
| Novocure Gmbh | $384.30 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Felicia Pharagood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.